2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018
Expert Consensus Document on the Management of Hyperkalaemia in Patients with Cardiovascular Disease Treated with Renin Angiotensin Aldosterone System Inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
GUIDELINE 11: Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD
Global burden of heart failure: a comprehensive and updated review of epidemiology
The ‘Ten Commandments’ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients with Heart Failure with Reduced Ejection Fraction: A Comparative Analysis of Three Randomised Controlled Trials
New! Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry
Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure Registry
Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry
Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
Unravelling the Interplay Between Hyperkalaemia, Renin-angiotensin-aldosterone Inhibitor Use and Clinical Outcomes: Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
Association Between Potassium Level and Outcomes in Heart Failure with Reduced Ejection Fraction: A Cohort Study from the Swedish Heart Failure Registry
Cardiovascular Risk Associated with Serum Potassium in the Context of Mineralocorticoid Receptor Antagonist Use in Patients with Heart Failure and Left Ventricular Dysfunction
Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review
Daily Home Monitoring of Potassium, Creatinine, and Estimated Plasma Volume in Heart Failure Post-discharge.
Patiromer Sorbitex Calcium for Hyperkalaemia
Recurrent Hyperkalaemia Management and Use of Renin–angiotensin–aldosterone System Inhibitors: A European Multi-national Targeted Chart Review
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors
Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN
Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
Potassium and the Use of Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data From BIOSTAT-CHF
Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project
Hyperkalemia: pharmacotherapies and clinical considerations
Consensus statement on the management of hyperkalaemia–an Asia-Pacific perspective
Long-term patiromer use and outcomes among US veterans with hyperkalemia and CKD: a propensity-matched cohort study
The Efficacy and Safety of New Potassium Binders on Renin-Angiotensin-Aldosterone System Inhibitor Optimization in Heart Failure Patients: A Systematic Review and Meta-Analysis
Evaluation of Longer- vs Short-Term Use of Patiromer on Health Care Resource Utilization in the Patiromer Longer-Term Use Evaluation (VALUE) Study
Recommendations for the Management of Hyperkalemia in Patients Receiving Renin-Angiotensin-Aldosterone System Inhibitors
The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta‑Analysis
Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebocontrolled, parallel-group study
Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia
Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study
Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN
Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project
Improving the outcome of patients with heart failure: assessment of iron deficiency and intravenous iron replacement
Hierarchical end points in prior heart failure trials and the HEART-FID trial
Increasing rates of screening and treatment of iron deficiency in ambulatory patients with heart failure with reduced ejection fraction: a quality improvement cohort study
Iron deficiency in heart failure with reduced ejection fraction: improving treatment on the cardiology ward
Early improvement of global longitudinal strain after iron deficiency correction in heart failure with reduced ejection fraction
Improving the Outcome of Patients With Heart Failure: Assessment of Iron Deficiency and Intravenous Iron Replacement
Iron Deficiency in Heart Failure: A Korea-Oriented Review
Intravenous Iron Supplementation Improves Energy Metabolism of Exercising Skeletal Muscles Without Effect on Either Oxidative Stress or Inflammation in Male Patients With Heart Failure With Reduced Ejection Fraction
Ferric Carboxymaltose in Heart Failure with Iron Deficiency
Treating Iron Deficiency in Heart Failure
Efficacy of Ferric Carboxymaltose in Heart Failure with Iron Deficiency: An Individual Patient Data Meta-Analysis
Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis
Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial
Criteria for Iron Deficiency in Patients with Heart Failure
Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?
Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial
Iron Deficiency in 78 805 People Admitted with Heart Failure Across England: A Retrospective Cohort Study
Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction
Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure
Iron Deficiency in Heart Failure: An Overview
Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient Data Meta-Analysis
Screening, Diagnosis and Treatment of Iron Deficiency in Chronic Heart Failure: Putting the 2016 European Society of Cardiology Heart Failure Guidelines into Clinical Practice
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency
Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It
Iron Deficiency in Heart Failure
Iron Deficiency & Anemia
Abnormalities of Potassium in Heart Failure
AHA 2020: New Insights on Iron Deficiency and Heart Failure
Clinical Implications of Managing Iron Deficiency from AFFIRM-AHF
Don’t Be Fooled: It’s Iron Deficiency, Not Just Anemia
Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial
Iron Deficiency and Anemia: What’s the Difference?
Iron Deficiency in Heart Failure
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Management of Heart Failure: Time to Consider New Options?
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes
Potassium Management
Potassium Management in Patients at Risk for Hyperkalemia
Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program
Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed
6-Minute Walk Test
AHA Heart Failure Tools and Resources for Patients
Heart Foundation of Australia Heart Failure Resources for Patients
ESC Heartfailurematters.org Patient Education Website
Potassium and Heart Failure